Abstract Acute coronary syndromes (ACS) are associated with high rates of morbidity and mortality. The advances of antiplatelet and anticoagulation therapy over several years time have resulted in improved in cardiac outcomes, but with increased health care costs. Multiple cost-effectiveness studies have been performed to evaluate the use of available antiplatelet agents and anticoagulation in the setting of both ST-segment elevation myocardial infarction (STEMI) and non-
Introduction
Acute coronary syndromes (ACS) refer to a spectrum of clinical presentations that result from decreased blood flow in the coronary arteries; the decrease in blood flow may range from a total or subtotal occlusion causing ST-segment elevation myocardial infarction (STEMI) to a significant but incomplete compromise of blood flow presenting as a non-ST-segment elevation acute coronary syndrome (NSTE-ACS), which includes non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA) [1] . ACS is one of the most common and costly hospital admissions in the USA, with a yearly estimate of 1.365 million hospitalizations associated with an approximate cost of US$150 billion [2, 3] . Similarly, ACS is associated with very high cost in Europe; this cost varies from around €1.9 billion in the UK, €1.3 billion in France, €3.3 billion in Germany, €3.1 billion in Italy and €1.0 billion in Spain [4] .
The management of ACS has undergone major changes after the introduction of percutaneous coronary intervention (PCI). While thrombolytic therapy used to be the primary choice of emergent reperfusion in STEMI, primary PCI within 120 min of presentation became the standard of care for reperfusion in STEMI. Similarly, the management of NSTE-ACS changed dramatically, from an era where only 30 % of these patients were revascularized to a new standard of care where early invasive strategy with PCI was done in the first 48 h when feasible (80-85 %) [5] . This shift was associated with major changes in the pharmacology used in this setting. The choice of antiplatelet agent used in addition to aspirin moved from the use of the platelet glycoprotein IIb/ IIIa receptor inhibitors (GPIs) exclusively during the 1990s to the adoption of P2Y 12 receptor antagonists with the introduction of clopidogrel (1997), prasugrel (2009) and ticagrelor (2011) . Similarly, the choice of antithrombotic agent has changed from exclusive use of heparin to include the use of low-molecular weight heparin (LMWH) and bivalirudin. The choice of antithrombotic, antiplatelet or a combination during the PCI varies from the combination of heparin and GPI at the beginning to the use of bivalirudin or heparin alone, which has been under debate recently.
The availability of many antiplatelet and antithrombotic agents as well as the countless possibilities for combination of these agents, with the potential benefits and risks of each in the setting of ACS, make it challenging for physicians to choose wisely. In this paper, we review the cost effectiveness of antiplatelet and antithrombotic agents. To better understand this literature, we first offer a brief perspective on cost effectiveness and decision making.
Cost-Effectiveness Analysis and Decision Making
The primary goal of cost-effectiveness analysis is to evaluate different health care intervention options in common terms so that policy makers and other decision makers can be informed on the most efficient method of producing extra health benefits from among the alternative ways that health care dollars can be distributed. The metric used to assess incremental cost effectiveness is the incremental cost-effectiveness ratio (ICER). An ICER is defined as the ratio of incremental costs to incremental health benefits of treatment 1 compared to treatment 2, or ICER = (C1 -C2)/(HB1 -HB2), where C1 and C2 are the cost for treatment 1 and 2, respectively, and HB1 and HB2 are the health benefits of treatment 1 and 2, respectively [6] . The ICER defines the cost that should be assumed for gaining one unit of output. In other words, if one of the alternatives is the usual practice, then it will tell us how much it will cost to gain a unit of outcome when moving from the usual practice to a new alternative. The health benefit may be measured in any sensible unit, such as number of myocardial infarctions (MIs) averted, but most studies use the conventional option of measuring clinical benefits as either the number of added life-years (LYs) or quality-adjusted life-years (QALYs) [6, 7] . Both of these approaches require estimation of life expectancy with and without the intervention being considered.
When assessing whether a treatment is cost effective, a requirement for a threshold can arise when policy makers seek a benchmark to compare different treatments and judge different studies. In general, wealthier countries may be willing to pay more (i.e., accept a higher threshold) for a given treatment than poorer countries [6, 8] . In the USA, a cost-effectiveness ratio of\US$50,000 per LY or QALY is frequently regarded as economically attractive, in part because it approximates the cost of providing chronic hemodialysis to patients with renal failure, at a cost that meets willingness-to-pay through Medicare [6] .
Conversely, a cost-effectiveness ratio of [US$100,000 per added LY or QALY is frequently regarded as economically unattractive. The range between these two benchmarks is the gray zone in which there is no consensus on whether a treatment is economically acceptable [6] . However, these benchmarks in the USA are really outdated; furthermore, assigning the same ICER threshold for different treatments in a wide range of diseases with different disease burdens may not be reasonable. Some countries may assign a general threshold for most cases, but allow for a higher threshold for treatment that relieves considerable burden of illness, i.e., ''the rule of rescue.'' For example, in the Netherlands, the average acceptable ICER is around €20,000, but an ICER of €80,000 per QALY will be acceptable for illnesses associated with a considerable disease burden [9] . Similarly, in Great Britain, the limit of an acceptable ICER varies between £20,000 and £30,000 depending on the burden of the disease [10] .
Literature Search Methodology
Relevant studies were identified through electronic searches of MEDLINE and the Cochrane Central Register of Controlled Trials databases. The search strategy used the terms ''cost effectiveness,'' ''antiplatelet,'' ''antithrombotic,'' and ''anticoagulation'' paired with ''acute coronary syndrome,'' ''non ST elevation MI,'' and ''ST elevation MI.'' In addition, we searched the bibliographies of relevant studies, reviews and editorial letters for articles that were written in English. Among 3026 articles, 88 were reviewed for the purpose of the review and 49 were used in the final version. Our choice for cost-effectiveness studies included both cost-effectiveness simulations using Markov models and cost-effectiveness analyses performed with randomized controlled trials (RCTs). While our original intention was to include cost-effectiveness analyses that were derived from observational studies, we ended up excluding these as they were very few and did not add to the content of our review.
Cost Effectiveness of Reperfusion in STSegment Elevation Myocardial Infarction
The management of STEMI witnessed major changes after the introduction of PCI. While thrombolysis was considered the mainstay therapy early on, primary PCI has become the standard of care currently, based on multiple trials that compared the two strategies. A meta-analysis of 22 pooled RCTs comparing PCI with thrombolysis showed that primary PCI was associated with a significant reduction in 30-day mortality in both patients who presented early and those who presented longer than 4 h after symptom onset [11] . PCI was associated with a higher early reperfusion rate and a higher proportion of patients achieving Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow [12] . Of the many trials comparing both strategies, economic assessment was available from two RCTs. The first of these is the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) trial that compared primary coronary angiography (PCA) to prehospital thrombolysis (PHT) in patients with STEMI. The thrombolysis strategy in this trial included the use of rescue PCI, as needed. The 1-year primary endpoint event rate (death, MI and stroke) was not different after PCA or PHT (14 vs. 16.4 %, P = NS). Although costs were lower in the PCA group during the in-hospital period (US$8287 vs. 9170, P = 0.0001), the cost of 1-year follow-up was higher in PTH group secondary to a higher rate of subsequent revascularizations in the PHT group [13] . It should be noted that these data are derived from a trial performed between 1997 and 2000 with a very long hospital stay that is not pertinent to current PCI care.
The Swedish Early Decision reperfusion Study (SWEDES) trial, reported in 2010, randomized 205 STEMI patients to be managed either with primary PCI with adjunctive enoxaparin and abciximab or with enoxaparin followed by reteplase. The clinical outcome did not differ significantly between the groups. Compared with the reteplase arm, PCI use was associated with a higher cost of intervention (US$4602 vs. US$3807, P = 0.047) and cost of drugs (US$1309 vs. US$1202, P = 0.001), but with a lower cost of hospitalization (US$7344 vs. US$9278, P = 0.025). At 1 year, there was a trend towards lower total cost and better quality-adjusted survival with PCI [US$25,315 and 0.759 added LY for PCI vs. US$27,819 and 0.728 added LY for reteplase, P = non significant (NS)] [14] .
These studies led to a shift in the primary reperfusion strategy in the USA. It is estimated that primary PCI is used in 85 % of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9 % and the combination of thrombolytic agents with PCI in 6 % [15] . This shift was associated with changes in the antiplatelet and anticoagulation agents used. The FRISC II trial compared an early invasive with an early non-invasive strategy in 2457 patients with NSTE-ACS. The results showed that the early invasive strategy was associated with a significant reduction the composite of death or MI (10.4 vs. 14.1 %, P = 0.005). There were also reductions in readmission (37 vs. 57 %, P \ 0.001) and revascularization after the initial admission with the early invasive strategy (7.5 vs. 31 %, P \ 0.01) [16] .
The economic analysis of FRISC II that was published in 2002 showed that at the end of 1 year, the early invasive strategy was associated with a US$3511 [23, 876 Swedish Krona (SEK)] higher cost compared with the non-invasive arm. The ICER for choosing the invasive instead of the non-invasive strategy was substantially high with US$206,470 per avoided death and US$94,852 per avoided death or MI [17] . However, it should be noted that what was called an early invasive approach in this trial was not associated with an early intervention. The intervention was done within 1 week and was associated with a longer hospital stay (12 vs. 8 days) . This trial does not represent the current early invasive strategy where PCI is performed within 48 h.
Reflecting more contemporary practice, the TACTICS-TIMI 18 trial randomized 2220 patients with UA/NSTEMI to either an early invasive strategy with routine catheterization and revascularization as appropriate within 48 h, or to a conservative, or ''selective invasive'' strategy, with catheterization performed only if the patient had objective evidence of recurrent ischemia or a positive stress test. All patients were provided with appropriate medical therapy. The early strategy was associated with a significant reduction in the composite of death and MI (7.3 vs. 9.5 %, P \ 0.05) [18] .
The economic analysis of the trial published in 2002 showed that the early invasive arm had higher initial costs (US$15,714 vs. US$14,047), but lower follow-up costs out to 6 months (US$6098 vs. US$7180), with similar cumulative 6-month costs (US$19,780 vs. US$19,111). Therefore, the early invasive strategy was shown to be cost effective, with an estimated ICER of US$13,000 per LY gained [19] . These data showed that adapting an early invasive approach with the intervention specifically done in the first 48 h was an economically attractive option.
Similar to the shift seen in the management of STEMI, primary PCI shifted as well from being used only for residual or recurrent ischemia to a standard of care where PCI is done in the first 48 h in approximately 80-85 % of the cases [5] . This shift was associated also with significant changes in the choice and sometimes in the duration of both antiplatelet and anticoagulation treatment.
Cost Effectiveness of Antiplatelet Therapy in ACS
The benefit of antiplatelet therapy in the setting of ACS was established first with aspirin in the Second International Study of Infarct Survival (ISIS-2) Trial. Aspirin, an inhibitor of platelet aggregation via inhibition of thromboxane A 2 , was found to be as effective as streptokinase in reducing mortality when used alone, and with better outcomes while both were used in combination in the setting of STEMI [20] . This trial demonstrated the importance of platelet aggregation in the setting of ACS and the potential benefit of using even more potent platelet activation inhibitors in this setting. This led first to the introduction of intravenous GPI in the management of ACS, followed later on by the introduction of oral P2Y 12 receptor antagonists. Table 1 shows the comparative and cost effectiveness of each of the currently available agents.
Cost Effectiveness of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors
Many trials evaluated the clinical and economic impact of using GPIs in the setting of ACS as well as after coronary interventions. One of the earliest of these trials is the Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis (RESTORE) Trial. In this trial, 2197 patients presenting with ACS and undergoing coronary intervention (balloon angioplasty or directional atherectomy) within 72 h of presentation were randomized to either tirofiban or placebo. The results showed that the use of tirofiban was associated with a significant reduction in the composite of death, MI and target vessel revascularization (TVR) at 2 days (8 vs. 12 %, P = 0.002). This difference was not statistically significant at 30 days (10.3 vs. 12.2 %, P = 0.16). There was no significant difference in the major bleeding rate between the two groups (5.3 vs. 3.7 %, P = 0.096) [21] . The economic evaluation of RESTORE published in 1998 showed that the cost of tirofiban use was not significantly higher than that for placebo with regard to inhospital costs (US$12,230 ± 5527 t vs. US$12,145 ± 5882, P = 0.75) or at 30 days (US$12,446 ± 5814 vs. US$12,402 ± 6147, P = 0.87) [22] . Another trial evaluating the efficacy of GPI is the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. In this trial 10,948 patients with ischemic chest pain were randomized to receive a bolus and infusion of either eptifibatide or placebo. For patients undergoing percutaneous revascularization within 72 h after randomization, eptifibatide use was associated with a significant reduction in the incidence of the composite of death or MI at 30 days (11.6 vs. 15.6 %, P = 0.01) [23] . Bleeding requiring transfusion was more common among patients treated with eptifibatide (11.6 vs. 9.2 %, P \ 0.001) [23] . An economic evaluation of the 3522 US patients enrolled in PURSUIT, published in 2000, showed that the use of eptifibatide was associated with a non-statistically significant US$372 cost advantage. The ICER for eptifibatide therapy was US$16,491 per LY gained and US$19,693 per QALY gained [24] .
In summary, the use of GPIs was shown in the early days to be an economically attractive option in the setting of ACS, when no other options were available in addition to aspirin in this patient population with highly aggregated platelet activity. However, it should be noted that the data from both RESTORE and PUSUIT trials are irrelevant to the contemporary era after the introduction of P2Y 12 receptor antagonists and bivalirudin. The use of GPI is confined now to high-risk patients as a bail out agent in addition to all other agents.
Cost Effectiveness of P2Y 12 Receptor Antagonists
The benefit of dual antiplatelet therapy (DAPT) was established with data showing that the combination of aspirin and ticlopidine was associated with higher platelet inhibition than aspirin alone in patients with coronary artery disease (CAD) treated with PCI [25] . However, ticlopidine use was associated with severe side effects. Subsequently, clopidogrel, a P2Y 12 receptor antagonist, was studied in multiple clinical trials and proved to be an effective option for DAPT with fewer side effects than ticlopidine. However, the use of clopidogrel was still associated with substantial interpatient variability and a delayed onset of action. The reduced pharmacologic response in some patients to clopidogrel was associated with an increased risk for adverse clinical events, including MI and stent thrombosis. This limitation of clopidogrel led to the introduction of the more potent antiplatelet agents such as prasugrel and ticagrelor. Several trials have evaluated the economics of using oral P2Y 12 receptor antagonists after PCI. The PCI-CURE substudy of the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial showed that the use of clopidogrel was associated with a significant reduction of the composite of cardiovascular death, MI or urgent TVR at 30 days (4.5 vs. 6.4 %, P = 0.03). Long-term administration of clopidogrel after PCI was associated with a lower rate of cardiovascular death, MI or any revascularization (P = 0.03) and with a 31 % reduction in cardiovascular death or MI (P = 0.002). There was no significant difference in major bleeding between the groups (P = 0.64) [26] .
The cost-effectiveness analysis of PCI-CURE, published in 2006, showed that clopidogrel was associated with a higher average cost at 1 year of US$253-US$423. For patients who underwent PCI during the initial hospitalization, the difference was less substantial and ranged from US$155 lower to US$90 higher with clopidogrel. Clopidogrel proved to be a very attractive option, with an ICER of US$2856-US$4775 per LY without PCI, and a dominant strategy in the early PCI subgroup [27] . Currently, with generic clopidogrel and the adoption of the early PCI strategy, the use of DAPT with clopidogrel will remain dominant when compared with aspirin alone.
After clopidogrel was established as both a clinically effective and cost-effective strategy for PCI, the role of the novel P2Y12 antagonist remained in question. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis in Myocardial Infarction (TRITON-TIMI-38) randomized 13,608 patients with moderate-to-high-risk ACS to receive either prasugrel or clopidogrel at the time of PCI. The study showed that prasugrel was associated with a significant reduction in the combined endpoint of cardiovascular death, nonfatal MI or nonfatal stroke (9.9 vs. 12.1 %, P \ 0.001), as well as a significant reduction in urgent TVR (2.5 vs. 3.7 %, P \ 0.001) and stent thrombosis (1.1 vs. 2.4 %, P \ 0.001). Patients receiving prasugrel, however, had significantly higher rates of major bleeding (2.4 % prasugrel vs. 1.8 % clopidogrel, P \ 0.03) [28] .
The cost-effectiveness analysis of the TRITON-TIMI-38 trial, published in 2010, showed that over 14.7 months follow-up, prasugrel was associated with net savings of US$221 per patient when compared with clopidogrel (US$26,067 vs. US$26,288). This saving was attributed to the lower rate of rehospitalizations involving PCI. Prasugrel was associated with life expectancy gains of 0.102 years [95 % confidence interval (CI) 0.030-0.180], primarily because of the decreased rate of nonfatal MI. Prasugrel was shown to be a dominant strategy [29] . This impact was more prominent in males, diabetic patients, STelevation MI and in patients with an age of \75 years, body weight C60 kg and no history of stroke/transient ischemic attack (TIA). The impact was less prominent in females, non-diabetic patients and those presenting with NSTEMI or those with a history of stroke/TIA. In patients with an age of C75 years, body weight \60 kg and a history of stroke/TIA, prasugrel was not associated with improvement in the clinical outcomes and was associated with similar costs. Figure 1 summarizes the cost assessment of prasugrel versus clopidogrel in the TRITON-TIMI-38 trial. However, this comparison was done between prasugrel and ''branded'' rather than lower cost ''generic'' clopidogrel. Thus, it is unclear whether prasugrel will remain an economically attractive alternative in comparison with generic clopidogrel.
The study of Platelet Inhibition and Patient Outcomes (PLATO) randomized 18,624 patients with moderate-tohigh-risk ACS to receive either ticagrelor or clopidogrel upstream or at the time of PCI. The study showed that the use of ticagrelor was associated with a significant reduction in the composite of death from vascular causes, MI or stroke (9.8 vs. 11.7 %, P \ 0.001). This reduction was significant as well in cardiovascular death (4.0 vs. 5.1 %, P = 0.001) and MI (5.8 vs. 6.9 %, P = 0.005), but not with stroke (1.5 vs. 1.3 %, P = 0.22). The use of ticagrelor was not associated with an increase risk of major bleeding (11.6 % ticagrelor vs.11.2 % clopidogrel, P = 0.43) [30] .
The economic evaluation of PLATO, reported in 2013, comparing ticagrelor to generic clopidogrel showed that even though ticagrelor use was associated with higher costs of €362, that was balanced by a QALY gain of 0.13 compared with generic clopidogrel at 1 year. Therefore, [31] . The attractiveness of ticagrelor is more prominent in patients with STEMI, NSTEMI, diabetic patients and to lesser degree in those presenting with UA. Nonetheless, the ICER for both QALYs and LYs was still economically attractive in all the ACS patients enrolled in PLATO. Figure 2 summarizes the cost effectiveness of ticagrelor versus clopidogrel as shown in the PLATO trial. In summary, the use of DAPT including oral P2Y 12 receptor antagonists is the standard of care as it represents the most reasonable option both clinically and economically. Deciding which agent should be used in the current era of generic clopidogrel in the USA is one the most debatable discussions in the interventional community. While it is well accepted that both ticagrelor and prasugrel offer superior clinical outcomes when compared with clopidogrel, the use of both agents in the setting of ACS remains less common in the USA than in Europe. Despite studies showing that both drugs are economically attractive options, their use is associated with a considerable economic burden on some patients in the USA who may not have the appropriate insurance to cover the extra cost of these medications in comparison to generic clopidogrel. If the use of these agents is not feasible in all ACS patients, a choice can be made to use these drugs in the patients who are likely to benefit the most. This group can be identified on the basis of available evidence from randomized control trials. For example, prasugrel use probably is more useful than clopidogrel in males, diabetics, younger patients (\65 years old) and those with a glomerular filtration rate (GFR) of [60 [28] . Similarly, ticagrelor use probably offers better outcomes than that of clopidogrel in those presenting with STEMI and NSTEMI (but not UA).
Cost Effectiveness of Antithrombotic use in ACS
The benefit of using unfractionated heparin (UFH) in addition to antiplatelet therapy in reducing the incidence of death and recurrent MI in the setting of ACS has been well established [32, 33] . However, the use of UFH is associated Fig. 1 The cost assessment of prasugrel versus clopidogrel in the TRITON-TIMI-38 trial. ACS acute coronary syndromes, MI myocardial infarction, TIA transient ischemic attack Fig. 2 The cost effectiveness of ticagrelor versus clopidogrel in the PLATO trial. ICER incremental cost-effectiveness ratio, LY life-year, NSTEMI non-ST-segment elevation myocardial infarction, QALY quality-adjusted life-year, STEMI ST-segment elevation myocardial infarction, UA unstable angina with an unpredictable anticoagulant response secondary to its neutralization by protein binding and activated platelets. Furthermore, the discontinuation of UFH is associated with an increased incidence of cardiac events [34] . Therefore, several studies were preformed to demonstrate the benefit of more predictable anticoagulation using enoxaparin/ LWMH, anti-Xa inhibitors and direct thrombin inhibitors. Table 2 shows these studies.
Cost Effectiveness of Enoxaparin (LowMolecular Weight Heparin)
The first comparison between UFH and enoxaparin in the setting of NSTEMI ACS came from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events (ESSENCE) Trial. This trial randomized 3171 patients with NSTEMI ACS to receive enoxaparin or continuous intravenous UFH. The use of enoxaparin was associated with a significant decrease in the incidence of the composite of death, MI or recurrent angina at 30 days (19.8 vs. 23.3 %, P = 0.016), as well as the need for revascularization at 30 days (27.1 vs. 32.2 %, P = 0.001).
Enoxaparin was associated with an increase in all bleeding (18.4 vs. 14.2 %, P = 0.001), primarily because of ecchymoses at injection sites, but a non-significant difference in the incidence of major bleeding (6.5 vs. 7.0 %, P = NS) [34] . The economic evaluation of ESSENCE, reported in 1998, showed that the use of enoxaparin was associated with net cumulative cost savings of US$1172 (P = 0.04) at 30 days and was therefore the dominant strategy [35] . The cost of enoxaparin in the contemporary era is even lower than when this comparison was done, and therefore it is expected that the results are still pertinent. Data comparing enoxaparin and UFH in the setting of STEMI comes from the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction TreatmentThrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 study. ExTRACT-TIMI 25 randomly assigned 20,506 patients with STEMI who were scheduled to undergo fibrinolysis to receive enoxaparin throughout the index hospitalization or weight-based UFH for at least 48 h. The use of enoxaparin was associated with a significant reduction in the incidence of the composite of death, nonfatal MI or urgent revascularization (11.7 vs. 14.5 %, P \ 0.001). However, enoxaparin use was associated with an increased incidence of major bleeding (2.1 vs. 1.4 %, P \ 0.001) [36] . Cost-effectiveness analysis of ExTRACT-TIMI 25, reported in 2009, showed that enoxaparin use in STEMI was associated with a higher cost at 30 days (US$102) and lifetime cost (US$1207). However, patients receiving enoxaparin gained an average of 0.12 LYs relative to patients given UFH. Enoxaparin was shown to be an economically attractive option, with an ICER of US$5700 per LY gained [37] . However, these data may not represent the contemporary practice where patients are managed primarily with primary PCI instead of fibrinolytic therapy.
Cost Effectiveness of Anti-Xa Inhibitors
The impact of the anti-Xa inhibitor fondaparinux on NSTE-ACS was evaluated in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) Trial. This trial randomized 20,078 NSTEMI ACS patients to fondaparinux or enoxaparin and reported no significant difference in the composite endpoint of death, MI or refractory ischemia at 9 days (5.8 vs. 5.7 %, P = NS), but fondaparinux did significantly reduce major bleeding events at 9 days (2.2 vs. 4.1 %, P \ 0.001) [38] . The economic evaluation of this trial in 2009 showed that using fondaparinux instead of enoxaparin was associated with a cost savings of US$547 per patient at 180 days, and longterm cost-effectiveness analysis found fondaparinux to be the dominant therapy [39] .
The OASIS-6 trial reported in 2009 evaluated the role of fondaparinux in STEMI. While fondaparinux was superior to UFH in preventing death or MI at 30 days in those receiving thrombolytic therapy [hazard ratio (HR) 0.79, P = 0.003], there was a higher incidence of guiding catheter thrombosis in the PCI cohort treated with fondaparinux compared with controls (n = 22 vs. n = 0, P \ 0.001) [40] . This finding made the use of this drug harmful with PCI, and the drug did not become the standard of care for the management of both STEMI and NSTE-ACS.
Cost Effectiveness of Direct Thrombin Inhibitors
The Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial randomized 13,819 patients with NSTE-ACS to one of three antithrombotic regimens: UFH or enoxaparin plus a GPI; bivalirudin plus a GPI; or bivalirudin monotherapy. The results showed that bivalirudin monotherapy when compared with heparin plus GPI was associated with a noninferior rate of the composite of death, MI or unplanned revascularization (9 vs. 8 %, P = 0.45), MI (6 vs. 6 %, P = 0.19) and unplanned revascularization (3 vs. 3 %, P = 0.87). However, the bivalirudin monotherapy was associated with significantly reduced rates of major bleeding (3.0 vs. 5.7 %, P \ 0.001). There was no difference in any of the outcomes between the use of UFH or enoxaparin plus a GPI and that of bivalirudin plus a GPI [41] .
The economic evaluation of the US cohort of the ACUITY trial, reported in 2008, showed that despite the higher drug cost of bivalirudin, the cumulative hospital stay costs were lowest with bivalirudin monotherapy (mean difference range US$184-US$1081, P \ 0.001 for overall comparison), with cost savings extending out to 30 days (mean difference range US$123-US$938, P = 0.005). This saving was primarily due to less major and minor bleeding with bivalirudin (US$8658/event and US$2282/ event, respectively) [42] . Figure 3 summarizes the cost assessment of the ACUITY trial.
The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial randomized 3602 patients with STEMI who presented within 12 h after the onset of symptoms and who were undergoing primary PCI to treatment with heparin plus a GPI or to treatment with bivalirudin alone. Similar to the findings in ACUITY, the use of bivalirudin monotherapy was associated with a reduced 30-day rate of net composite of major bleeding and major adverse cardiovascular and cerebral events (MACCE), including death, MI, TVR and stroke (9.2 vs. 12 %, P = 0.005), a lower rate of major bleeding (4.9 vs. 8.3 %, P \ 0.001), a lower 30-day cardiac death (1.8 vs. 2.9 %, P = 0.03) and death from all causes (2.1 vs. 3.1 %, P = 0.047) [43] . The economic evaluation of the HORIZONS-AMI trial, reported in 2012, showed that the use of bivalirudin monotherapy was associated with lifetime savings of £267 (£12 843 vs. £13 110). Probabilistic analysis showed that bivalirudin use was associated with higher quality-adjusted survival and lower costs in 95.0 % of simulation runs. In 99.2 %, cost effectiveness was better than £20,000 per QALY gained, suggesting that bivalirudin monotherapy is a cost-effective strategy when compared with heparin and GPI [44] . Figure 4 summarizes the cost assessment of the HORIZONS-AMI trial.
However, data from both ACUITY and HORIZONS-AMI did not utilize a treatment arm with heparin monotherapy. It stands to reason that heparin monotherapy may be as effective as, if not more effective than, bivalirudin monotherapy at a decreased cost. The How Effective Are Antithrombotic Therapies in Primary PCI (HEAT-PPCI) trial that randomly assigned 1917 STEMI patients undergoing emergency angiography to either UFH or bivalirudin showed that the use of bivalirudin compared with heparin was associated with a higher incidence of the primary composite outcome of death, MI, Stroke and TVR (8.7 vs. 5.7 %, P = 0.01), without changing the incidence of major bleeding (3.5 vs. 3.1 %, P = 0.59) [45] . The cost analysis of this trial has not been reported yet; however, heparin is less expensive than bivalirudin, and given that its use is associated with lower cost and better outcomes without increasing the risk of complications, heparin will probably be a dominant strategy according to this trial.
On the other hand, the BivaliRudin in acute myocardial Infarction versus Glycoprotein IIb/IIIa and Heparin Trial (BRIGHT) showed contrasting results to those of HEAT-PPCI. In this trial, 2194 patients were randomized in a 1:1:1 fashion to receive either bivalirudin alone, heparin alone, or heparin plus tirofiban. The results showed that the Fig. 3 The cost assessment of the ACUITY trial. GPI glycoprotein IIb/IIIa receptor inhibitor, NSTEMI non-STsegment elevation myocardial infarction, UA unstable angina, UFH unfractionated heparin Fig. 4 The cost assessment of the HORIZONS-AMI trial. GPI glycoprotein IIb/IIIa receptor inhibitor, UFH unfractionated heparin composite 30-day net adverse clinical event (NACE) endpoint (MACCE ? bleeding) was lower in the bivalirudin arm compared with both the heparin monotherapy and heparin plus tirofiban arms (8.8 vs. 13.2 vs. 17 %, P \ 0.001). This was driven predominantly by a reduction in the risk of Bleeding Academic Research Consortium (BARC) 3-5 (major) bleeding (0.5 vs. 1.5 vs. 2.1 %, P = 0.04) and BARC 2-5 bleeding (1.2 vs. 3.6 vs. 5.1 %, P \ 0.001). Stent thrombosis rates at 30 days were similar (0.6 vs. 0.9 vs. 0.7 %, P = 0.77). Similarly, at 1 year, NACE rates were lowest in the bivalirudin arm (12.8 vs. 16.5 vs. 20.5 %, P \ 0.001); MACCE rates were similar (6.7 vs. 7.3 vs. 6.8 %, P = 0.9) [46] . The cost-effectiveness data for this trial have not been reported yet. A costeffectiveness comparison between bivalirudin monotherapy and heparin monotherapy will be crucial for decision makers, especially given the conflicting clinical outcomes and huge discrepancy of the cost of both strategies.
In summary, the choice of anticoagulation in the ACS setting may differ depending on many factors, including the presentation (STEMI vs. NSTE-ACS) and the invasive approach. While multiple studies showed that the use of more predictable anticoagulation with enoxaparin in the medical management of NSTE-ACS was associated with cost savings when compared with UFH, these economic comparisons are based on a study where only 26-32 % underwent coronary revascularization [with only 18-22 % of patients undergoing percutaneous transluminal coronary angioplasty (PTCA)]. In fact, a part of the cost saving with enoxaparin was related to a lower rate of both diagnostic catheterization and PTCA in the enoxaparin group. Furthermore, the revascularization in these patients was done on average within 6 days [34] . Therefore, whether enoxaparin is still necessarily more cost effective in the contemporary era with early revascularization done in the first 48 h and more potent antiplatelet agents being used is debatable. As for fondaparinux, the higher incidence of catheter thrombosis diminished it use in NSTE-ACS to a great extent. On the other hand, the use of enoxaparin in STEMI was not cost saving, but was still an attractive economical choice. However, given the improvement in door to balloon time and the increased evidence of potential benefit of UFH in PCI, and the potential increase risk of bleeding reported with LMWH, the use of LMWH in STEMI may be impractical.
During primary PCI, the use of bivalirudin monotherapy seems to be a more attractive option than the combined use of UFH or enoxaparin with GPI in both NSTE-ACS and STEMI. Cost-effectiveness analysis showed that bivalirudin is a dominant strategy. This led to an increase adoption of bivalirudin use in the USA and further decline in the routine use of GPI. However, there is an argument that the use of heparin monotherapy might be an attractive alternative to bivalirudin monotherapy both clinically and economically. This was supported by the HEAT-PPCI trial and a large meta-analysis that showed heparin to be superior to bivalirudin [45, 47] . However, another RCT (the BRIGHT trial) and a meta-analysis using RCT data showed that bivalirudin was associated with similar efficacy outcomes, with a lower rate of bleeding [46, 48] . The debate on the appropriate anticoagulation to use in ACS will continue for a while and cost-effectiveness analyses comparing both agents might offer an insight to direct the decision.
Cost Effectiveness of Different Antiplatelet and Anticoagulation Agents in ACS
Another aspect of the current debate in the interventional community is related to the choice of the best combination of available antiplatelet and anticoagulation agents that can offer the best results clinically and economically. The only data from RCTs that address this important issue in the setting of ACS come from the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 study, which was reported recently, in 2014. The trial originally aimed to randomize 1240 STEMI patients to prasugrel plus bivalirudin or clopidogrel plus heparin. The study was stopped prematurely after enrolling 548 patients and showed no difference between prasugrel plus bivalirudin and clopidogrel plus heparin in NACE (15.6 vs. 14.5 %, P = 0.68), MACCE (4.8 vs. 5.5 %, P = 0.894) and bleeding (14.1 vs. 12.0 %, P = 0.543) [48] . However, this trial was stopped prematurely because of slow enrollment and therefore may be underpowered. More studies are needed to provide an insight to this crucial issue.
Conclusion
The use of an ideal antiplatelet as a second agent changed over time depending not only on effectiveness and safety, but also in part on the cost effectiveness of the agents. Several considerations should be taken into account when deciding which agents to use. These include the effectiveness of the studied agent in reducing major adverse cardiac and cerebrovascular events, and the associated increase or decrease in bleeding rate. The cost consideration is not only linked to the direct cost of the drug itself, but also to the decreased or increased cost associated with added or reduced benefit or risk of using any agent when compared with either placebo or other available therapeutic options. The debate on the most attractive choice of antiplatelet and anticoagulation agents will continue. In the next 5 years, the first patent for prasugrel (2017) and ticagrelor (2018) will expire, which may allow for generic forms of both drugs to become available. Furthermore, more data addressing comparative and cost effectiveness in studies comparing UFH and bivalirudin will be available and hopefully will provide an insight on the best agent to be used. The debate of the effectiveness of longer versus 12 months of DAPT especially in high-risk ACS patients and the cost effectiveness of each approach may impact our choice of therapy [49] . More studies similar to BRAVE 4 comparing the comparative and cost effectiveness of different antiplatelet and anticoagulation agents are expected to help guide decision making.
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